Dennis Burton, PhD
Scripps Research Joint Appointments
Other Joint Appointments
The Ragon Institute of MGH, MIT and HarvardIAVI Neutralizing Antibody Center, The Scripps Research Institute
Research Focus
Antibodies and Infectious Disease
The perception of man as the easy victor over microbes has changed dramatically in the last two decades. Vaccination has offered protection against a number of viral pathogens, but it is increasingly recognized that the strategies used in the past will not be successful against all viruses. We are focused on developing rational vaccine strategies, particularly against HIV and particularly using an approach termed “Reverse Vaccinology 2.0”. In this approach, broadly neutralizing antibodies isolated from natural HIV infection are investigated in interaction with their sole viral target, the HIV Envelope, and the data used to guide immunogen design and immunization strategies. Immunogens are then evaluated in detail in animal models and the results used to iteratively improve immunogens as we move toward an HIV vaccine suitable to protect humans.
Education
Ph.D. (Physical Biochemistry), Lund University, 1978B.A. (Chemistry), University of Oxford, 1974
Professional Experience
2015-2017 Chairman, Immunology and Microbial Science (IMS), Scripps Research1991-2017 Professor, Immunology and Microbial Science (IMS), Scripps Research
2015-2015 Distinguished Lecturer, The American Association of Immunologists
-2012 Professor (Joint Appointment), Molecular Biology, Scripps Research
1990-1991 Personal Chair, The University of Sheffield
1989-1991 Visiting Member, Research Institute of Scripps Clinic
1985-1991 Jenner Fellow, Lister Institute of Preventive Medicine
1987-1990 Senior Lecturer in Biochemistry, The University of Sheffield
1981-1987 Lecturer in Biochemistry, The University of Sheffield
1980-1981 Junior Research Fellow, Wolfson College, University of Oxford
1979-1981 Medical Research Council Training Fellowship, University of Oxford
Selected References
Ferrara, F., Erasmus, M. F., D'Angelo, S., Leal-Lopes, C., Teixeira, A. A., Choudhary, A., Honnen, W., Calianese, D., Huang, D. L., Peng, L., Voss, J. E., Nemazee, D., et al. A pandemic-enabled comparison of discovery platforms demonstrates a nai''ve antibody library can match the best immune-sourced antibodies. (2022). Nature Communications, 13. PMCID: PMC8786865.
Agostinetto, R., Rossi, M., Dawson, J., Lim, A., Simoneau, M. H., Boucher, C., Valldorf, B., Ross-Gillespie, A., Jardine, J. G., Sok, D., Burton, D. R., Hassell, T., et al. Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools. (2022). Biotechnology and Bioengineering, PMCID: PMC8652680.
van Schooten, J., van Haaren, M. M., Li, H., McCoy, L. E., Havenar-Daughton, C., Cottrell, C. A., Burger, J. A., van der Woude, P., Helgers, L. C., Tomris, I., Labranche, C. C., Montefiori, D. C., et al. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. (2021). PLoS Pathogens, 17. PMCID: PMC8423243.
Antanasijevic, A., Sewall, L. M., Cottrell, C. A., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Silverman, J. B., Groschel, B., Georgeson, E., Bhiman, J., Bastidas, R., LaBranche, C., et al. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. (2021). Nature Communications, 12. PMCID: PMC8355326.
Turner, H. L., Andrabi, R., Cottrell, C. A., Richey, S. T., Song, G., Callaghan, S., Anzanello, F., Moyer, T. J., Abraham, W., Melo, M., Silva, M., Scaringi, N., et al. Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. (2021). Science Advances, 7. PMCID: PMC8318364.
Rissanen, I., Krumm, S. A., Stass, R., Whitaker, A., Voss, J. E., Bruce, E. A., Rothenberger, S., Kunz, S., Burton, D. R., Huiskonen, J. T., Botten, J. W., Bowden, T. A., et al. Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen. (2021). mBio, 12. PMCID: PMC8406324.
Allen, J. D., Chawla, H., Samsudin, F., Zuzic, L., Shivgan, A. T., Watanabe, Y., He, W. T., Callaghan, S., Song, G., Yong, P., Brouwer, P. J. M., Song, Y. T., et al. Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. (2021). Biochemistry, 60(27), 2153-2169. PMCID: PMC8262170.
Bakowski, Malina A., Beutler, N., Wolff, Karen C., Kirkpatrick, Melanie G., Chen, Emily, Nguyen, Tu-Trinh H., Riva, Laura and Shaabani, Namir, Parren, Mara and Ricketts, James, Gupta, Anil K., Pan, Kastin and Kuo, Peiting, Fuller, MacKenzie and Garcia, Elijah, Teijaro, J. R., et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. (2021). Nature Communications, 12. PMCID: PMC8175350.
Yuan, M., Huang, D. L., Lee, C. C. D., Wu, N. C., Jackson, A. M., Zhu, X. Y., Liu, H. J., Peng, L. (141479, Van Gils, M. J., Sanders, R. W., Burton, D. R., Reincke, S. M., et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. (2021). Science, 373(6556), 818-+. PMCID: PMC8284396.
Song, G., He, Wan-ting and Callaghan, Sean, Anzanello, Fabio and Huang, Deli, Ricketts, James, Torres, Jonathan L., Beutler, N., Peng, L., Vargas, Sirena and Cassell, Jon, Parren, Mara and Yang, Linlin, Ignacio, Caroline, Smith, Davey M., Voss, J. E., et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. (2021). Nature Communications, 12. PMCID: PMC8134462.